Kronos Bio IncNASDAQ:KRON
- LAST PRICE0.7507
- TODAY'S CHANGE (%)0.0117 (1.5832%)
- Bid / Lots0.7409/ 1
- Ask / Lots0.7650/ 97
- Open / Previous Close0.7300 / 0.7390
- Day Range
- 52 Week Range
- Volume167,738
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KRON |
|---|---|---|
| 09:32 ET | 775 | 0.73 |
| 09:36 ET | 3000 | 0.721 |
| 09:43 ET | 100 | 0.7301 |
| 09:48 ET | 100 | 0.74 |
| 09:57 ET | 2500 | 0.74 |
| 10:06 ET | 7499 | 0.7356 |
| 10:08 ET | 100 | 0.7312 |
| 10:17 ET | 900 | 0.7301 |
| 10:19 ET | 14150 | 0.74 |
| 10:26 ET | 135 | 0.744949 |
| 10:44 ET | 200 | 0.7482 |
| 10:46 ET | 1200 | 0.749401 |
| 10:48 ET | 766 | 0.7494 |
| 10:51 ET | 11630 | 0.741 |
| 11:06 ET | 100 | 0.745 |
| 11:38 ET | 1474 | 0.7449 |
| 11:40 ET | 100 | 0.7429 |
| 11:49 ET | 608 | 0.743 |
| 11:54 ET | 100 | 0.7449 |
| 12:00 ET | 150 | 0.7449 |
| 12:03 ET | 7300 | 0.745 |
| 12:05 ET | 19468 | 0.7499 |
| 12:07 ET | 300 | 0.7537 |
| 12:09 ET | 2652 | 0.7678 |
| 12:14 ET | 882 | 0.7688 |
| 12:23 ET | 2153 | 0.7678 |
| 12:34 ET | 700 | 0.7678 |
| 12:43 ET | 5000 | 0.755 |
| 12:59 ET | 479 | 0.75965 |
| 01:08 ET | 100 | 0.7678 |
| 01:21 ET | 242 | 0.7687 |
| 01:30 ET | 2950 | 0.760187 |
| 01:33 ET | 208 | 0.7678 |
| 01:37 ET | 9800 | 0.7687 |
| 01:42 ET | 3839 | 0.76 |
| 01:51 ET | 487 | 0.7644 |
| 01:57 ET | 16542 | 0.7601 |
| 02:00 ET | 9609 | 0.7688 |
| 02:02 ET | 10100 | 0.7516 |
| 02:04 ET | 100 | 0.7516 |
| 02:13 ET | 3400 | 0.764 |
| 02:15 ET | 1998 | 0.765 |
| 02:18 ET | 100 | 0.764 |
| 02:24 ET | 100 | 0.764 |
| 02:27 ET | 200 | 0.7501 |
| 02:29 ET | 100 | 0.764 |
| 02:33 ET | 100 | 0.764 |
| 02:38 ET | 700 | 0.7573 |
| 02:40 ET | 100 | 0.7501 |
| 02:49 ET | 500 | 0.7638 |
| 02:51 ET | 400 | 0.761 |
| 03:05 ET | 3387 | 0.7501 |
| 03:07 ET | 100 | 0.7637 |
| 03:20 ET | 100 | 0.751 |
| 03:27 ET | 300 | 0.7569 |
| 03:39 ET | 2523 | 0.76127 |
| 03:41 ET | 700 | 0.757 |
| 03:43 ET | 12100 | 0.751 |
| 03:52 ET | 100 | 0.751 |
| 03:56 ET | 100 | 0.751 |
| 03:59 ET | 622 | 0.7507 |
May 23, 2024
May 22, 2024
Kronos Bio to Participate in Three Upcoming Healthcare Conferences and Events, from 4:30PM ET on Wednesday May 22, 2024 by Dow Jones
4:30PM ET on Wednesday May 22, 2024 by Dow Jones
May 21, 2024
DJ Kronos Bio Hires Ex-Senti Bio CFO to Head Finances, Operations, from 8:48AM ET on Tuesday May 21, 2024 by Dow Jones
8:48AM ET on Tuesday May 21, 2024 by Dow JonesPress Release: Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer, from 8:15AM ET on Tuesday May 21, 2024 by Dow Jones
8:15AM ET on Tuesday May 21, 2024 by Dow JonesKronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer, from 8:15AM ET on Tuesday May 21, 2024 by Dow Jones
8:15AM ET on Tuesday May 21, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kronos Bio Inc | 47.5M | -0.4x | --- |
Kezar Life Sciences Inc | 50.5M | -0.5x | --- |
Evogene Ltd | 37.7M | -1.5x | --- |
LAVA Therapeutics NV | 59.4M | -2.2x | --- |
DURECT Corp | 53.1M | -1.8x | --- |
BioLine RX Ltd | 58.4M | -0.9x | --- |
Company Information
Kronos Bio, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics that target the deregulated transcription that causes cancer and other serious diseases. It is developing KB-0742, its internally discovered oral cyclin dependent kinase 9 (CDK9) inhibitor, for the treatment of MYC-amplified and others transcriptionally addicted solid tumors. It has initiated the Phase 2 portion of its Phase 1/2 clinical trial for KB-0742. It is also developing KB-9558, which inhibits the lysine acetyltransferase (KAT) domain of p300, a critical node of the IRF4 TRN. IRF4 is a key transcription factor driver in multiple myeloma and KB-9558 selectively targets its activity. Its scientific focus is on developing medicines that target deregulated transcription, the hallmark of cancer and other serious diseases. Using its Small Molecule Microarray (SMM) platform or other approaches, it can generate and advance small molecule starting points into drug development candidates.
Contact Information
- Headquarters
- 1300 S. El Camino Real, Suite 400SAN MATEO, CA, United States 94402
- Phone
- 650-781-5200
- Fax
- 302-636-5454
Executives
- Non-Executive Independent Chairman of the Board
- Arie Belldegrun
- President, Chief Executive Officer, Director
- Norbert Bischofberger
- Chief Financial Officer, Chief Operating Officer, Chief Accounting Officer
- Deborah Knobelman
- Chief Scientific Officer
- Christopher Dinsmore
- Director
- Joshua Kazam
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $47.5M |
|---|---|
Revenue (TTM) | $7.6M |
Shares Outstanding | 60.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.80 |
EPS | $-2.00 |
Book Value | $2.70 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | 6.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,651.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
